Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility

Title:Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility

Volume: 27 Issue: 35

Author(s): Priscila M. Joáo Job, Francislaine A. dos Reis Lívero and Arquimedes G. Junior*

Affiliation:

• Laboratory of Cardiovascular Pharmacology (LaFaC), Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, MS,Brazil

Keywords: Blood pressure, cardiovascular disease, chronic disease, drug discovery, epigenomic, gene, phenotype.

Abstract: Hypertension is a common chronic disease that particularly affects the elderly and can trigger several cardiovascular conditions. Although the treatment of hypertension has evolved in recent decades, many hypertensive patients still do not have properly controlled blood pressure. Accumulating evidence supports the hypothesis that DNA methylation plays an important role in regulating gene expression, altering the phenotype and function of the cardiovascular system. The present review highlights recent advances in research on DNA methylation in the development of hypertension. Several preclinical and clinical evidence show that methylation of different targets appears to be involved in hypertension. Studies of the involvement of DNA methylation have greatly improved our understanding of hypertension, but its use as a valid therapeutic target is still unknown. Further studies could help to bring to light the truth about gene therapy in hypertension.

Cite this article as:

Joáo Job M. Priscila , dos Reis Lívero A. Francislaine and Junior G. Arquimedes*, Epigenetic Control of Hypertension by DNA Methylation: A Real Possibility, Current Pharmaceutical Design 2021; 27 (35) . https://dx.doi.org/10.2174/1381612827666210322141703